Why 2026 Is The Year AI Becomes A Partner, Not Just A Processor, In Drug Development

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.

Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needsAI-driven ...
GEN - Genetic Engineering and Biotechnology News

Lilly Grows AI Footprint with Up-to-$2.75B Insilico Collaboration

The big pharma and AI drug developer expand on a partnership that launched with a 2023 software licensing accord.
Contract Pharma

How AI Is Reshaping Early Drug Development Through a Landmark Partnership

Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic ...
Fierce Biotech

Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...
GlobalData on MSN

Simulations Plus and three pharma companies collaborate on AI-driven drug development

The collaborations will use Simulations Plus software platforms, including ADMET Predictor, GastroPlus, Thales, and ...

BullFrog AI unveils decision engine to tackle drug development uncertainty

BullFrog AI Holdings Inc. BFRG on Wednesday introduced bfARENAS, a scenario-based decision engine. The engine aims at ...

AI Is Reshaping Neuroprotective Drug Discovery Market: New BCC Research Pulse Report Maps the Investment and Innovation Landscape

"A new Pulse Report from BCC Research, AI Impact on Neuroprotective Agents, provides a comprehensive analysis of how AI is ...